Every 424B that Onconetix, Inc. (ONCO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ONCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCO filings page.
Onconetix, Inc. (ONCO) is registering for resale by a single Selling Stockholder up to 100,000,000 shares of common stock, all issuable upon conversion of a portion of 37,812 shares of Series F preferred stock. This is a resale registration; the company is not selling any securities and will not receive proceeds from any share sales, though it will cover registration expenses. Assuming full issuance, the registered shares would equal 2,282% of common shares outstanding as of August 28, 2026 and would raise the post-offering share count to 104,380,522 from 4,380,522, indicating very high potential dilution. The Series F converts initially at $0.9767 per share and is constrained by Nasdaq’s 20% exchange cap and a 4.99%/9.99% beneficial ownership limitation until stockholder approvals increase authorized shares and lift caps.
Onconetix describes itself as a commercial-stage biotech focused on oncology diagnostics, led by its Proclarix prostate cancer test, and notes it has abandoned commercialization of ENTADFI. The company reports recurring losses, an accumulated deficit of about $138.3 million and cash of about $5.9 million as of June 30, 2026, and discloses that these factors raise substantial doubt about its ability to continue as a going concern, making additional equity facilities, preferred financings and the pending Realbotix share exchange central to its funding plans.
Onconetix, Inc. registered 100,000,000 shares of Common Stock for resale on behalf of Keystone Capital Partners, LLC under an equity line of credit (ELOC). The registration covers shares that have been or may be issued to Keystone under an October 2, 2024 ELOC Purchase Agreement.
The company states it will not sell securities under this prospectus and will not receive proceeds from secondary sales by Keystone under this registration. Separately, Onconetix may receive up to $25 million in aggregate gross proceeds from sales to Keystone under the ELOC; through June 5, 2026, approximately 2.6 million split-adjusted shares were sold for aggregate proceeds of about $11.3 million. Shares outstanding were 3,691,492 prior to this registration; issuance of all 100,000,000 registrable shares would imply 103,691,492 shares outstanding on the stated assumptions.
Onconetix is registering up to 25,000,000 shares of Common Stock for resale on behalf of Keystone Capital Partners under an equity line of credit (ELOC). The registration covers shares that have been or may be issued to Keystone under a Common Stock ELOC Purchase Agreement.
The Company will not receive proceeds from resale under this prospectus, but may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement. Through April 24, 2026, the Company sold approximately 701,933 split-adjusted shares under the ELOC for aggregate proceeds of approximately $8.1 million. Shares outstanding were 11,464,572 as of April 24, 2026; if all ELOC shares were issued, pro forma outstanding would be 36,464,572 shares (assuming the illustrative pricing described in the ELOC).
Onconetix, Inc. filed a prospectus registering up to 5,100,000 shares of common stock for resale by Keystone Capital Partners under an equity line of credit (“ELOC”). We are not selling any securities in this offering, and will not receive proceeds from sales by the selling stockholder. Separately, the company may sell shares to Keystone under the ELOC and may receive up to $25.0 million in aggregate gross proceeds, subject to market-driven pricing and other limitations.
Through November 7, 2025, the company sold approximately 661,762 shares under the ELOC for aggregate proceeds of about $7.1 million. Our common stock last closed at $2.74 on Nasdaq. As of November 7, 2025, 1,555,010 shares were outstanding. The purchase price to Keystone is based on prevailing market prices as defined in the agreement, and resales by Keystone could create dilution and affect the stock price. Under the ELOC, 30% of gross proceeds from each sale must be applied to redeem Series C Preferred Stock.